Medigen Vaccine Biologics Corporation (高端) announced on the 6th that its net loss per share for the first three quarters was NT$0.44, with the third-quarter loss narrowing significantly to NT$0.07. To meet demand for enterovirus vaccines and new product lines, the company plans to invest NT$870 million in a new production line at the Zhubei Third Biotechnology Building and simultaneously prepare convertible bonds and private placements to strengthen its medium- to long-term global operations.

Medigen’s operations are gradually improving. The company posted a third-quarter loss of approximately NT$22 million, showing a clear contraction compared with previous quarters. The net loss attributable to the parent company for the first three quarters was NT$143 million, with a net loss per share of NT$0.44.

To address long-term demand for its existing enterovirus vaccine (EV71) in Southeast Asia and other markets, while also supporting the R&D and future mass production of next-generation vaccines, Medigen will build a new production line at the Zhubei Third Biotechnology Building, with an estimated capital expenditure of NT$870 million.

CEO Li Ssu-Hsien noted that the Southeast Asian market for enterovirus vaccines requires millions of doses, and the company is currently awaiting regulatory approval in Vietnam. In addition, for medium- to long-term planning, Medigen is developing vaccines targeting globally prevalent enteroviruses, covering high-income markets such as Japan, South Korea, and Europe, with overall market size and pricing potential surpassing traditional regional markets.

Li stated that, leveraging Medigen’s experience in enterovirus vaccine development, the new product technologies can build upon existing platforms, which is expected to improve development efficiency and shorten the time to market.

To support the production expansion and new product development, Medigen plans to issue convertible bonds (CBs) and conduct a private placement for fundraising.

The convertible bonds are planned at NT$750 million, with joint guarantees from two financial institutions. The initial construction phase will be funded using the company’s own capital.

Additionally, the company plans a private placement of up to 40 million shares (approximately 40,000 units) and is currently negotiating with several potential investors, though the plan has not yet been finalized. Medigen emphasized that the private placement requires shareholder approval, and an extraordinary general meeting is scheduled for December 24 to handle the relevant proposals.

Medigen stated that this production expansion and fundraising plan aims to proactively prepare for the international vaccine market over the next 5–10 years. With new product lines addressing globally relevant needs, the company expects to gradually expand from regional markets to high-income markets including Japan, South Korea, and Europe, thereby strengthening its operational growth momentum.

Resource: 高端擬斥資8.7擴大疫苗產線、啟動募資布局全球市場